title: 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys.
abstract: We report here on the ability of IDRA 21 and aniracetam, two negative allosteric modulators of glutamate-induced DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization, to attenuate alprazolam-induced learning deficit in patas monkeys working in a complex behavioral task. In one component of a multiple schedule (repeated acquisition or "learning"), patas monkeys acquired a different four-response chain each session by responding sequentially on three keys in the presence of four discriminative stimuli (geometric forms or numerals). In the other component (performance) the four-response chain was the same each session. The response chain in each component was maintained by food presentation under a fixed-ratio schedule. When alprazolam (0.1 or 0.32 mg/kg p.o.) was administered alone, this full allosteric modulator of gamma-aminobutyric acid type A (GABAA) receptors produced large decreases in the response rate and accuracy in the learning component of the task. IDRA 21 (3 or 5.6 mg/kg p.o.) and aniracetam (30 mg/kg p.o.) administered 60 min before alprazolam, having no effect when given alone, antagonized the large disruptive effects of alprazolam on learning. From dose-response studies, it can be estimated that IDRA 21 is approximately 10-fold more potent than aniracetam in antagonizing alprazolam-induced learning deficit. We conclude that IDRA 21, a chemically unrelated pharmacological congener of aniracetam, improves learning deficit induced in patas monkeys by the increase of GABAergic tone elicited by alprazolam. Very likely IDRA 21 exerts its behavioral effects by antagonizing AMPA receptor desensitization.
authors.affiliation: Nathan S. Kline Institute for Psychiatric Research, Center for Neuropharmacology, Orangeburg, NY 10962, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Thompson
authors.forename: A
authors.initials: A
authors.lastname: Guidotti
authors.forename: M
authors.initials: M
authors.lastname: DiBella
authors.forename: E
authors.initials: E
authors.lastname: Costa
mesh_terms: D000525:Alprazolam / Q000494:pharmacology*; D000818:Animals; D001581:Benzothiadiazines / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects; D004192:Discrimination, Psychological; D004305:Dose-Response Relationship, Drug; D004901:Erythrocebus patas; D005260:Female; D007858:Learning / Q000187:drug effects*; D007859:Learning Disabilities / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D011760:Pyrrolidinones / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology; D013329:Structure-Activity Relationship
chemical_list: D001581:Benzothiadiazines; D011760:Pyrrolidinones; D011963:Receptors, GABA-A; C091420:IDRA 21; C036466:aniracetam; D000525:Alprazolam